Speaker illustration

Professor David Cherney

University of Toronto, Toronto (Canada)

Mediators of the effect of ertugliflozin on a composite kidney outcome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV

Event: ESC Congress 2021 - The Digital Experience

Topic: Renal Failure and Cardiovascular Disease

Session: Cardiovascular Disease in Special Populations ePosters

Thumbnail

This platform is supported by

logo Novo Nordisk